Bioscience Reports,
Год журнала:
2024,
Номер
44(4)
Опубликована: Апрель 1, 2024
Since
1975,
the
incidence
of
obesity
has
increased
to
epidemic
proportions,
and
number
patients
with
quadrupled.
Obesity
is
a
major
risk
factor
for
developing
other
serious
diseases,
such
as
type
2
diabetes
mellitus,
hypertension,
cardiovascular
diseases.
Recent
epidemiologic
studies
have
defined
development
neurodegenerative
Alzheimer's
disease
(AD)
types
dementia.
Despite
all
these
comorbidities
associated
obesity,
there
still
lack
effective
antiobesity
treatment.
Promising
candidates
treatment
are
anorexigenic
neuropeptides,
which
peptides
produced
by
neurons
in
brain
areas
implicated
food
intake
regulation,
hypothalamus
or
brainstem.
These
efficiently
reduce
body
weight.
Moreover,
because
proven
interconnection
between
AD,
potential
neuroprotective
effects
two
agents
animal
models
neurodegeneration
been
examined.
The
objective
this
review
was
explore
neuropeptides
acting
within
brain,
emphasizing
their
not
only
but
also
disorders.
Frontiers in Nutrition,
Год журнала:
2024,
Номер
11
Опубликована: Апрель 29, 2024
Obesity,
a
chronic
global
health
problem,
is
associated
with
an
increase
in
various
comorbidities,
such
as
cardiovascular
disease,
type
2
diabetes
mellitus,
hypertension,
and
certain
types
of
cancer.
The
increasing
prevalence
obesity
requires
research
into
new
therapeutic
strategies.
Glucagon-like
peptide-1
receptor
agonists,
specifically
semaglutide
liraglutide,
designed
for
mellitus
treatment,
have
been
explored
drugs
the
treatment
obesity.
This
minireview
describes
molecular
mechanisms
liraglutide
different
metabolic
pathways,
its
mechanism
action
processes
appetite
regulation,
insulin
secretion,
glucose
homeostasis,
energy
expenditure,
lipid
metabolism.
Finally,
several
clinical
trial
outcomes
are
described
to
show
safety
efficacy
these
management.
Frontiers in Nutrition,
Год журнала:
2024,
Номер
11
Опубликована: Апрель 3, 2024
The
review
present
data
on
the
intricate
relationship
between
bariatric
surgery,
gut
microbiota,
and
metabolic
health
in
obesity
treatment.
Bariatric
is
recognized
as
an
effective
intervention
for
managing
morbid
obesity,
including
various
techniques
with
distinct
mechanisms
of
action,
efficacy,
safety
profiles
Roux-en-Y
Gastric
Bypass
(RYGB),
Sleeve
Gastrectomy
(SG),
Laparoscopic
Adjustable
Banding
(LAGB),
Biliopancreatic
Diversion
(BPD).
RYGB
SG
are
most
prevalent
procedures
globally,
inducing
microbiota
changes
that
influence
microbial
diversity
abundance.
Post-surgery,
alterations
bacterial
communities
occur,
such
increased
Escherichia
coli
inversely
correlated
fat
mass
leptin
levels.
During
digestion,
produce
physiologically
active
compounds
like
bile
acids
(Bas)
short-chain
fatty
(SCFAs).
SCFAs,
derived
by
fermentation,
appetite,
energy
metabolism,
obesity-related
pathways.
Bas,
altered
modulate
glucose
metabolism
insulin
sensitivity.
Furthermore,
enhance
incretin
secretion,
particularly
glucagon-like
peptide
1
(GLP-1).
Therefore,
understanding
after
surgery
could
be
crucial
predicting
outcomes
developing
targeted
interventions
management.
Food and Agricultural Immunology,
Год журнала:
2024,
Номер
35(1)
Опубликована: Авг. 2, 2024
Since
the
1990s
worldwide
rate
of
obesity
has
escalated
significantly.
This
overflow
affects
all
demographic
groups,
with
a
notable
impact
on
older
adults
and
women.
Obesity
is
associated
variety
serious
chronic
health
conditions.
Additionally,
it
linked
to
endocrine
disorders
such
as
hypothyroidism
subclinical
hypothyroidism.
review
analyzes
connection
between
micronutrient
levels,
particularly
focusing
vitamin
D,
evaluates
potential
nutritional
supplementation
approaches
for
this
population.
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(7), С. 2011 - 2011
Опубликована: Март 29, 2024
Obesity
is
associated
with
several
chronic
conditions
including
diabetes,
cardiovascular
disease,
and
metabolic
dysfunction-associated
steatotic
liver
disease
malignancy.
Bariatric
surgery,
most
commonly
Roux-en-Y
gastric
bypass
sleeve
gastrectomy,
an
effective
treatment
modality
for
obesity
can
improve
comorbidities.
Over
the
last
20
years,
there
has
been
increase
in
rate
of
bariatric
surgeries
growing
epidemic.
Sleeve
gastrectomy
widely
performed
surgery
currently,
while
it
serves
as
a
durable
option
some
patients,
important
to
note
that
complications,
leak,
stenosis,
fistula,
gastrointestinal
hemorrhage,
gastroesophageal
reflux
may
occur.
Endoscopic
methods
manage
post-sleeve
complications
are
often
considered
due
risks
reoperation,
endoscopy
plays
significant
role
diagnosis
management
complications.
We
perform
detailed
review
current
endoscopic
Journal of Agricultural and Food Chemistry,
Год журнала:
2024,
Номер
72(32), С. 17924 - 17937
Опубликована: Июль 4, 2024
Turmeric,
derived
from
Curcuma
longa,
and
Lactobacillus
paracasei,
a
lactic
acid
bacteria,
have
been
studied
for
their
potential
antiobesity
effects.
To
date,
the
effects
of
turmeric
fermented
with
L.
paracasei
not
sufficiently
investigated.
This
study
was
conducted
via
oral
administration
5%
paracasei-fermented
(FT)
unfermented
(UT)
in
diet
over
16
weeks
using
high-fat
(HFD)-induced
obese
C57BL/6J
mice.
Results
showed
that
curcuminoid
content
decreased
following
fermentation.
Furthermore,
FT
significantly
suppressed
weight
gain
liver
visceral
adipose
tissue
reduced
plasma
metabolic
parameters
both
UT
experimental
groups.
The
were
more
noticeable
than
those
form.
Moreover,
downregulated
expression
adipogenesis,
lipogenesis,
inflammatory-related
protein,
but
upregulated
β-oxidation
protein
SIRT
1,
PPARα,
PGC-1α
perigonadal
tissue.
Additionally,
ameliorated
insulin
resistance
by
activating
receptor
pathway
expressions
tissues.
also
modulated
gut
microbiota
composition,
particularly
two
beneficial
Akkermansia
muciniphila
Desulfovibrio,
as
well
short-chain
fatty
acid-producing
bacteria:
Muribaculum
intestinale
Deltaproteobacteria.
Our
findings
indicate
modulation
effect
may
be
an
important
its
mechanisms.
Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity,
Год журнала:
2025,
Номер
30(1)
Опубликована: Янв. 9, 2025
To
report
data
on
the
real-world
effectiveness
and
safety
of
injectable
(IS)
oral
(OS)
therapies
in
obese
or
overweight
diabetes
(T2DM)
patients
glycometabolic
control,
weight
loss
(WL)
maintenance
after
use
semaglutide.
175
subjects
with
obesity
T2DM
were
retrospectively
assessed.
Of
these,
129
(75F,
54
M;
mean
age
61.2
±
9.8
years)
treated
IS
46
(24F,
22
65.7
12.8
OS
for
WL.
At
baseline,
(mW)
was
101.8
24.6
kg
95.2
15.0
kg;
body
mass
index
(mBMI)
36.7
8.7
kg/m2
34.3
5.3
kg/m2.
After
6
months,
group,
127
had
a
mW
mBMI
reduction
−
10.4
8.1
3.9
3.0
group
6.7
2.6
2.1
12
102
achieved
9.3
7.5
3.4
44
treatment
10.7
6.5
2.4
24
92
therapy
15.9
11.4
5.8
3.7
There
percentage
glycated
hemoglobin
(HBA1C)
1.9
1.4%,
1.5
1.9%,
1.7%
6,
months
group.
In
there
1.6%
0.8
0.6%
therapy.
Semaglutide
induces
WL
treatment.
Our
results
show
comparable
overweight.
provide
significant
that
allows
reaching
therapeutic
goal
short
time.
Level
Evidence
II
